DSGN Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Design Therapeutics Inc's (DSGN) financial performance, focusing on its profitability and a comparison with competitors. While the company's gross, operating, and net margins are not available, it reports a Return on Equity (ROE) of -30.70%. DSGN, with a market capitalization of $692.58M, is benchmarked against ANRO and ARVN to assess its financial standing within the market.
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month High - Here's What Happened
Design Therapeutics (NASDAQ:DSGN) reached a new 52-week high of $11.30, trading up approximately 2% on Thursday. The company reported better-than-expected Q1 EPS and has a "Moderate Buy" consensus rating from analysts with an average price target of $15.20. Institutional investors hold a significant portion of the stock, and the company is developing small molecule therapeutic drugs for genetic diseases.
Design Therapeutics, Inc. Appoints David Shapiro, M.D. as Class III Director and as Nominating and Corporate Governance Committee Member, Effective March 31, 2026
Design Therapeutics, Inc. announced the appointment of David Shapiro, M.D., to its Board of Directors as a Class III director, effective March 31, 2026. Dr. Shapiro will also serve on the Nominating and Corporate Governance Committee, with his term as director concluding at the company's 2027 annual meeting of stockholders.
Director David Shapiro granted 67,500 DSGN stock options (DSGN)
Design Therapeutics director David Shapiro was granted 67,500 new stock options. These options include a grant for 60,000 shares vesting over 36 months and another for 7,500 shares vesting over 12 months, both with an exercise price of $10.64 and expiring on March 30, 2036. This transaction represents compensation awards rather than open-market trading.
Design Therapeutics (DSGN) director David Shapiro submits Form 3
Design Therapeutics, Inc. director David Shapiro has submitted a Form 3, which is an initial statement of beneficial ownership of securities. This filing registers his status as a reporting person with the SEC. The Form 3 indicates no reportable transactions or holdings, meaning it solely serves to acknowledge his director position without disclosing any current share ownership or trading activity.
David Shapiro joins Design Therapeutics (DSGN) board with equity awards
Design Therapeutics, Inc. announced the appointment of David Shapiro, M.D., to its Board of Directors as a Class III director, effective March 31, 2026. Dr. Shapiro will also serve on the Nominating and Corporate Governance Committee. His compensation includes an annual cash retainer for Board and committee service, along with significant equity awards including an initial option to purchase 60,000 shares and a prorated annual option for 7,500 shares.
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96
The article reports that Design Therapeutics (DSGN) has experienced a 12.82% increase in its price target, raising it to $14.96. The content itself is not available, but the headline indicates a positive adjustment in analyst expectations for the company's stock.
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
This DelveInsight report analyzes the Fuchs Dystrophy pipeline landscape for 2026, highlighting over five key companies developing new treatment therapies. It covers clinical trials, therapy mechanisms, and FDA updates, noting significant emerging therapies like K-321, TTHX1114, and DT-168. The report also details a recent Phase I trial by Design Therapeutics for DT-168, showing favorable safety and tolerability results for Fuchs endothelial corneal dystrophy (FECD).
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
A DelveInsight report indicates that over five companies are actively developing more than five treatment therapies for Fuchs Dystrophy, a progressive eye disease affecting the cornea. Key companies like Kowa Pharmaceutical, Trefoil Therapeutics, and Design Therapeutics are advancing therapies such as K-321, TTHX1114, and DT-168 through various clinical trial stages. Design Therapeutics recently announced positive Phase I trial results for DT-168, an eye drop designed to reduce mutant TCF4 gene expression associated with the condition.
DSGN Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Design Therapeutics Inc (DSGN), emphasizing that the overall technical consensus for the stock is a "Buy." It details various technical indicators such as Moving Averages, RSI, MACD, and identifies key support and resistance levels. The analysis highlights that most indicators suggest a positive outlook for DSGN, despite some mixed signals from shorter-term moving averages.
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst
Design Therapeutics (DSGN) recently received a "Buy" rating and a $15.00 price target from Leerink Partners analyst Faisal Khurshid. Another "Buy" rating came from Craig-Hallum's Adam Vogel, though TipRanks – OpenAI reiterated a "Hold" rating. The company reported a Q4 GAAP net loss of $16 million.
Jefferies initiates coverage of Design Therapeutics (DSGN) with buy recommendation
Jefferies has initiated coverage of Design Therapeutics (DSGN) with a "buy" recommendation. This signifies a positive outlook from the investment bank regarding the company's stock performance.
Jefferies Initiates Coverage On Design Therapeutics with Buy Rating, Announces Price Target of $15
Jefferies has initiated coverage on Design Therapeutics (NASDAQ:DSGN) with a Buy rating. The firm has also set a price target of $15 for the company's stock. This article is a headline-only piece, typical of real-time intelligence for traders.
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program
Design Therapeutics (NASDAQ:DSGN) has outlined its plans for key data readouts in the second half of the year for its Friedreich’s ataxia (FA) program (RESTORE-FA), an exploratory Phase 2 biomarker study for Fuchs’ endothelial corneal dystrophy (FECD), and a preclinical program for myotonic dystrophy type 1 (DM1). The company aims to demonstrate an increase in endogenous frataxin in FA patients, assess splicing engagement in FECD using corneal tissue, and progress its DM1 candidate DT-818, which has shown significant reduction in toxic DMPK RNA preclinically. Design Therapeutics also states it has over $200 million in cash, funding its operations into 2029 with a goal of achieving positive clinical proof-of-concept in at least one program.
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from five brokerages, with an average one-year price target of $15.25. The company recently reported better-than-expected Q4 EPS of ($0.27), surpassing the ($0.38) estimate, although analysts project ($0.91) EPS for the current fiscal year. Institutional investors hold a significant 56.64% of the stock, which trades near $10.12 with a market cap of $624.1 million.
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report
SR One Capital Fund I Aggregator, SR One Capital Partners I, SR One Capital Management, and Simeon George have filed an amended Schedule 13D/A for Design Therapeutics, Inc. The report shows a decrease in their beneficial ownership percentages due to an increase in the issuer's outstanding common stock. Aggregator, Partners I, and Parent each report beneficial ownership of 10.6% of outstanding shares, while Dr. Simeon George reports 10.7%.
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade
Design Therapeutics (NASDAQ:DSGN) saw its stock price increase by 6.7% after Royal Bank of Canada raised its price target from $13.00 to $14.00, maintaining an "outperform" rating. The company also reported an EPS beat for the last quarter, and institutional investors now hold a significant portion of its stock. Despite unusual light trading volume, the stock closed higher at $10.66.
RBC Capital raises Design Therapeutics stock price target on programs
RBC Capital has increased its price target for Design Therapeutics (NASDAQ:DSGN) to $14.00 from $13.00, maintaining an Outperform rating, following the company's Q4 2025 earnings report. The firm highlighted favorable risk-reward for Design Therapeutics' two key programs, DT-216p2 for Friedreich’s ataxia and DT-168 for Fuchs Endothelial Corneal Dystrophy, with data expected in the second half of 2026. This adjustment comes as the stock has seen significant appreciation, and analysts believe the company's geneTAC platform holds substantial long-term potential.
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock
Royal Bank of Canada has increased its price target for Design Therapeutics (NASDAQ:DSGN) stock from $13.00 to $14.00, reiterating an "outperform" rating and projecting a potential upside of 30.9%. The biopharmaceutical company, focused on small-molecule therapies for genetic diseases, has a "Moderate Buy" consensus rating from analysts with an average target price of $15.25. DSGN shares opened at $10.70, and institutional investors own 56.64% of the company's stock.
Piper Sandler reiterates Overweight on Design Therapeutics stock
Piper Sandler has reiterated an Overweight rating and a $12 price target for Design Therapeutics Inc (NASDAQ:DSGN), noting the company's pipeline is on track for a catalyst-rich year. Key upcoming data includes 12-week topline data for DT-216P2 in H2 2026 and Phase 2 biomarker data for DT-168 also in H2 2026. Design Therapeutics ended Q4 2025 with strong cash reserves, holding more cash than debt.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics announced its financial results for the fourth quarter and full year 2025, highlighting progression across its GeneTAC® portfolio. The company is advancing three clinical programs with anticipated data and patient dosing milestones in 2026 and 2027 for Friedreich Ataxia (DT-216P2), Fuchs Endothelial Corneal Dystrophy (DT-168), and Myotonic Dystrophy Type-1 (DT-818). Design Therapeutics reported a cash position of $219.8 million at year-end 2025, projected to fund operations into 2029.
GeneTAC pipeline advances at Design Therapeutics (NASDAQ: DSGN) in FA, FECD, DM1 and HD
Design Therapeutics (NASDAQ: DSGN) is advancing its GeneTAC small-molecule genomic medicines pipeline across multiple nucleotide repeat expansion diseases, including Friedreich ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), myotonic dystrophy type-1 (DM1), and Huntington’s disease (HD). Key programs like DT-216P2 for FA, DT-168 for FECD, and DT-818 for DM1 are progressing through clinical trials, with significant updates and patient dosing expected in 2026 and 2027. The company's GeneTAC platform aims to address the underlying genetic causes of these debilitating conditions by modulating gene transcription.
Design Therapeutics (Nasdaq: DSGN) widens 2025 loss but keeps $219.8M cash
Design Therapeutics reported a wider net loss of $69.8 million in 2025 due to increased R&D spending on its GeneTAC® programs. Despite the loss, the company maintains a strong cash position of $219.8 million, which is expected to fund operations into 2029. Design Therapeutics is advancing three clinical programs for Friedreich ataxia, Fuchs endothelial corneal dystrophy, and myotonic dystrophy type-1, with key data readouts anticipated in 2026 and 2027.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting ongoing clinical trials for DT-216P2 (Friedreich Ataxia) and DT-168 (Fuchs Endothelial Corneal Dystrophy), with data expected in the second half of 2026. The company also anticipates initiating patient dosing for DT-818 (Myotonic Dystrophy Type-1) in the first half of 2026. Design Therapeutics reported a cash position of $219.8 million as of year-end 2025, which is expected to fund operations into 2029.
DSGN: GeneTACⓇ platform advances four programs for genetic diseases, with strong clinical and financial momentum
DSGN's GeneTACⓇ small molecules are progressing in four programs targeting severe monogenic disorders, with three in clinical stages and one preclinical. The lead candidates show promising efficacy and safety, with key data readouts anticipated in 2026–2027 and sufficient cash to fund operations until 2029. This update is based on Design Therapeutics, Inc. [DSGN] Slides Release from March 9, 2026.
Three genetic disease trials push ahead at Design Therapeutics
Design Therapeutics reported its fourth-quarter and full-year 2025 financial results, announcing cash, cash equivalents, and investment securities of $219.8 million, expected to fund operations into 2029. The company is advancing three clinical programs: DT-216P2 for Friedreich Ataxia and DT-168 for Fuchs Endothelial Corneal Dystrophy, both with data anticipated in H2 2026, and DT-818 for Myotonic Dystrophy Type-1, with patient dosing planned in H1 2026. Despite a net loss of $69.8 million in 2025, the company maintains a strategy focused on building a diversified clinical pipeline for genetic diseases with high unmet needs.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics, a clinical-stage biotechnology company, announced its fourth quarter and full-year 2025 financial results and key business updates. The company is advancing three clinical programs: DT-216P2 for Friedreich Ataxia, DT-168 for Fuchs Endothelial Corneal Dystrophy, and DT-818 for Myotonic Dystrophy Type-1, with significant data readouts and patient dosing expected in 2026. Design Therapeutics reported a year-end cash position of $219.8 million, which is projected to fund operations into 2029.
Design Therapeutics (NASDAQ:DSGN) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS
Design Therapeutics (NASDAQ:DSGN) reported first-quarter earnings of ($0.27) per share, surpassing the consensus estimate of ($0.38) by $0.11. The company's stock traded down 4.05% on Tuesday to $9.95, with a market capitalization of $566.81 million. Analysts have a "Moderate Buy" rating on DSGN, with an average target price of $15.25.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX)
Analysts have mixed opinions on Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) within the healthcare sector. Design Therapeutics received a "Strong Buy" consensus with a 57.8% upside, while Vertex Pharmaceuticals also garnered a "Strong Buy" consensus with a 23.6% upside, despite some analysts maintaining a "Hold" rating. The reports highlight specific price targets and analyst ratings for both companies.
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
Design Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its GeneTAC® portfolio. The company is advancing three clinical programs, including FA, FECD, and DM1, with anticipated data readouts and patient dosing expected in 2026. Design Therapeutics reported a net loss of $69.8 million for the year and maintains a strong cash position of $219.8 million, projected to fund operations into 2029.
Design Therapeutics Inc expected to post a loss of 35 cents a share - Earnings Preview
Design Therapeutics Inc (DSGN) is anticipated to report a loss of 35 cents per share. This information comes from an earnings preview provided by Refinitiv and Reuters. The article is a brief financial update regarding the company's expected performance.
DSGN - Design Therapeutics, Inc. Latest Stock News & Market Updates
This page provides the latest news and market updates for Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company focused on degenerative genetic diseases. It highlights the company's GeneTAC pipeline progress, financial results, and corporate events. Recent updates include details on their IPO, Q1 2021 financial results, and clinical trial plans for Friedreich ataxia.
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
DelveInsight's report on the Fuchs Dystrophy pipeline highlights over 5 key companies developing 5+ treatment therapies for the condition, including Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, and Santen. The report provides a comprehensive assessment of these pipeline products, covering their mechanism of action, clinical study status, and developmental activities. It also discusses market drivers such as the aging population and opportunities, as well as obstacles like a lack of awareness and universal treatment guidelines.
DSGN Stock News Today | Earnings, Events & Price Alerts
This page provides a compilation of recent news and events related to Design Therapeutics (DSGN) stock, including its price performance and significant company announcements. The news highlights include stock movements, participation in investor conferences, clinical data presentations, and financial results. Currently, there are no upcoming events, monitor news, or earnings analysis specifically for DSGN listed on this page.
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
This article provides an overview of the Fuchs Dystrophy treatment pipeline in 2026, highlighting key companies like Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, and Santen, and the therapies they are developing. DelveInsight's report details clinical trial statuses, mechanisms of action, and routes of administration for these emerging treatments. The article also mentions Design Therapeutics' favorable Phase I trial results for DT-168, a GeneTAC small molecule, which shows promise for Fuchs endothelial corneal dystrophy (FECD).
Fuchs Dystrophy Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen
This DelveInsight report, "Fuchs Dystrophy Pipeline Insight, 2026," provides a comprehensive overview of the global pipeline for Fuchs Dystrophy treatments, detailing over five key companies and therapies in various stages of clinical development. It highlights the mechanism of action, route of administration, and clinical trial status of emerging drugs, including a promising Phase I trial from Design Therapeutics. The report also addresses market dynamics, such as increasing demand due to the aging population, and challenges like a lack of awareness about the disease.
Design Therapeutics Highlights GeneTAC Pipeline, FA Data Timeline and DM1 Dosing Plans at Oppenheimer Conference
Design Therapeutics (NASDAQ: DSGN) outlined its GeneTAC pipeline progress at an Oppenheimer conference, including upcoming data for Friedreich's ataxia (FA) in late 2026 and plans to begin dosing DM1 patients in the first half of 2026. The company's small-molecule approach aims to modulate gene expression for single-gene disorders, with preclinical data showing promising results for DT-216 in FA, DT-818 in DM1, and DT-168 eye drops in Fuchs' endothelial corneal dystrophy (FECD). Design Therapeutics reported $206 million in cash at the end of Q3, providing runway for its clinical programs toward proof-of-concept.
Design Therapeutics (NASDAQ:DSGN) Hits New 1-Year High - What's Next?
Design Therapeutics (NASDAQ:DSGN) recently hit a new 52-week high of $11.01, driven by positive analyst sentiment with a consensus "Moderate Buy" rating and a $15.00 average price target. The biopharmaceutical company focuses on developing small-molecule therapies for genetic diseases using its GeneTAC platform, with lead programs addressing Friedreich ataxia, myotonic dystrophy type 1, Fuchs endothelial corneal dystrophy, and Huntington's disease. Despite the stock's recent surge, some analysts and rating agencies still maintain a more cautious outlook.
DSGN: Clinical-stage genetic medicine programs in FA, FECD, and DM1 advance toward key data readouts
Design Therapeutics, Inc. (DSGN) provided updates on its small molecule genetic medicine platform, showcasing clinical advancements in Friedreich's ataxia (FA), Fuchs endothelial corneal dystrophy (FECD), and Myotonic dystrophy type 1 (DM1). The company anticipates key data readouts from these programs in the second half of this year and next year. DSGN confirmed it has strong financial resources to support the ongoing clinical trials.
DSGN Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Design Therapeutics, Inc. (DSGN), including its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2024 and Q3 2025. The company reported $0 in revenue and a net loss of -$49.6M in FY2024, showing weak financial health with a Piotroski F-Score of 2/9 and low-quality earnings. The analysis highlights negative free cash flow and a limited cash runway.
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners Global Healthcare Conference. Management will provide presentations at both virtual and in-person events in late February and early March 2026. The company is a clinical-stage biotechnology firm focused on developing GeneTAC® gene targeted chimera small molecules for degenerative genetic diseases.
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. The company, a clinical-stage biotechnology firm, will have its management present at these virtual and in-person events to discuss its GeneTAC® gene targeted chimera small molecules platform and its pipeline of therapies for degenerative genetic diseases.
Short Interest in Design Therapeutics, Inc. (NASDAQ:DSGN) Drops By 14.0%
Short interest in Design Therapeutics, Inc. (NASDAQ:DSGN) decreased by 14.0% in January, totaling 1,993,557 shares, representing approximately 4.6% of the company's float. The days-to-cover ratio is 5.6 days based on an average trading volume of 354,260 shares. Analysts generally maintain a "Moderate Buy" consensus rating with a price target of $15.00, and institutional investors own roughly 56.6% of the stock.
Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Design Therapeutics, Inc. (NASDAQ:DSGN) has received a consensus "Moderate Buy" rating from five analysts, with an average one-year price target of $15.00. The company's stock opened at $10.07, and institutional investors currently hold 56.64% of its shares. Design Therapeutics focuses on developing small molecule therapeutic drugs for genetic diseases using its GeneTAC platform.
Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics, Inc. (Nasdaq: DSGN) announced its participation in two upcoming investor conferences: the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, and the Leerink Partners Global Healthcare Conference on March 10, 2026. The company is a clinical-stage biotechnology firm focused on developing GeneTAC® gene targeted chimera small molecules for serious degenerative genetic diseases. They have programs in development for conditions like Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease.
Design Therapeutics (NASDAQ:DSGN) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen has upgraded Design Therapeutics (NASDAQ:DSGN) from a "sell" to a "hold" rating. The company currently has an average target price of $15.00 and a "Moderate Buy" consensus rating from analysts. Design Therapeutics, a biopharmaceutical company, focuses on developing small molecule therapeutic drugs for genetic diseases, utilizing its GeneTAC platform.
Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
Design Therapeutics is drawing investor attention due to upcoming clinical data readouts and financial updates related to its GeneTAC platform for rare genetic disorders. The company's financial position is strong, with $245.5 million in cash, cash equivalents, and marketable securities as of the end of 2024, expected to fund operations into 2029. This ample funding provides a significant buffer for its ongoing clinical development programs.
Design Therapeutics announces governance-driven board resignation
Design Therapeutics (DSGN) announced that board member Deepa Prasad will resign effective February 1, 2026, due to conflict-avoidance policies related to her new role at a major bank. The company faces weak financial performance despite a strong balance sheet, with analysts currently rating the stock as a "Hold" with a $10.00 price target. TipRanks' AI Analyst also rates DSGN as "Neutral" due to financial struggles, though technical indicators are supportive.
Design Therapeutics, Inc. Announces Resignation of Deepa Prasad from the Company's Board of Directors, Effective February 1, 2026
Design Therapeutics, Inc. announced that Deepa Prasad will resign from its Board of Directors, effective February 1, 2026. Her resignation is due to conflict-avoidance policies related to a new role she has accepted with a major bank. The company, a biotechnology firm, is involved in developing treatments for genetic diseases such as Friedreich ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease.
Design Therapeutics (NASDAQ:DSGN) Reaches New 1-Year High - Here's What Happened
Design Therapeutics (NASDAQ:DSGN) recently hit a new 52-week high of $10.97, closing at $10.59 with significant trading volume. Analyst sentiment for the biopharmaceutical company, which focuses on genetic repeat-expansion diseases, is a "Moderate Buy" with an average price target of $15.00, despite some mixed individual ratings. The company also reported an EPS beat and shows substantial institutional ownership, with firms like RA Capital and JPMorgan increasing their stakes.
